A recent phase I study evaluating the use of pembrolizumab in patients with NSCLC showed an objective response rate of 19. 4% with a median duration of response of 12. 5 months (40). anti-tumor immune responses. This fusion of tumor immunology and genetics is leading to new ways to target this class of ideal tumor-specific antigens and could allow the application of immunotherapy to many cancers. Adoptive T-cell transfer can mediate in vivo tumor regression as demonstrated by murine tumor models and clinical responses in trials using autologous tumor-infiltrating lymphocytes (TIL) derived from human melanomas (1). Further work has shown that the native T-cell response in TIL can recognize a variety of tumor-associated antigens (TAA) expressed in the context of MHC. However , difficulties in finding reactive T-cell populations for transfer for most other cancer types prompted studies to understand the molecular nature of the antigens recognized Everolimus (RAD001) by clinically effective TIL. In parallel with these studies, highly efficient methods for genetically modifying human T-cells have been developed that have allowed the transduction of tumor-reactive T-cell receptors into lymphocytes for use in clinical trials. This review will also summarize the development of methods for identifying tumor associated antigens in the context of T-cell immunotherapy and present the prominent findings that have shaped our understanding of T-cell based immunological tumor rejection and pointed the way to new treatment approaches in cellular immunotherapy. The molecular identification of human TAA began with the demonstration of tumor-reactive T-cells in cancer patients. These could be acquired either from peripheral blood lymphocytes (stimulated in vitro) (2) or from culturing tumor-infiltrating lymphocytes resident in many Everolimus (RAD001) melanomas (3). The major factors that determine whether an antigen is a good target are 1) tumor-specificity 2) immunogenicity (ability to generate a T-cell response, often measured by tumor recognition, cytokine release, and/or cytolysis) 3) prevalence and level of expression on tumor cells. There are several strategies that can be employed to identify the antigens mediating T-cell recognition of tumor and selecting one approach versus another can lead to finding very different types of antigens. == Background == The earliest efforts to molecularly define the precise antigens on tumors responsible for T-cell recognition were based on the seminal work by the group of Boon (4). First working with murine tumors and then with human melanoma, they showed that genes encoding antigens could be identified by screening tumor DNA libraries by transfecting them into cell lines that expressed the proper MHC allele for presentation, but were not recognized. Then by adding the tumor-reactive T-cell clone from peripheral blood, the gene conferring recognition could be identified when it triggered TNF release from the T-cells. Although very labor intensive, this method was the initial way that a large number of such antigens were discovered by multiple investigators. It required starting with a tumor reactive T-cell, so most such antigens were Everolimus (RAD001) associated with human melanoma. The observation that TIL from melanoma, when expanded in vitro with IL-2, frequently displayed autologous tumor recognition, made it a ready source of T-cells to be used in antigen cloning. In addition Everolimus (RAD001) , the fact that human melanomas could frequently be established as stable tumor lines in vitro (unlike other common human epithelial cancers) facilitated the demonstration that T-cells could indeed be tumor reactive. Van der Bruggen was the first to identify MAGE-1, a cancer-germline antigen, as a melanoma-associated antigen recognized by T-cells (5). Tumor-germline antigens are characterized by their expression in the testis and on tumors. Epitopes from these antigens are not acknowledged in the testis, as those cells do not express Class I MHC, thereby making them attractive targets for T-cell immunotherapy (Table I). This was then followed with the discoveries that a series of proteins associated with pigment production in melanomas and melanocytes were frequently targets for T-cells. This Rabbit polyclonal to EPM2AIP1 latter class of antigens, often referred to as tissue differentiation antigens (normal proteins expressed as a consequence of a specific function of the target tissue), constituted the majority of TAA initially discovered. This was because in melanomas and melanocytes, they were very highly expressed and therefore were over-represented in cDNA libraries from these tissues. In addition , to avoid the burdensome task of making many cDNA libraries, if a tumor was cross-recognized by other allogeneic T-cells (via a common MHC allele), its cDNA library was often screened rather.